LungTalk for Increasing Lung Cancer Screening

Overseen By Francis Valenzona

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Hackensack Meridian Health

Disqualifiers: Lung cancer, Impaired decision-making, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to discover better methods to encourage lung cancer screening. It tests two approaches: a tailored communication tool called LungTalk (a digital tool for lung cancer screening communication) and a standard video from the American Cancer Society. The goal is to determine which method more effectively increases screening rates among high-risk individuals. Suitable candidates for this trial include those who have smoked the equivalent of a pack a day for 20 years or more and either still smoke or quit within the past 15 years. As an unphased trial, this study provides a unique opportunity to contribute to innovative strategies that could enhance lung cancer screening and potentially save lives.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that the LungTalk digital tool is safe for increasing lung cancer screening?

Research has shown that LungTalk is a tool designed to help people better understand lung cancer screening by using technology to provide personalized advice. Studies have found that tools like LungTalk can reduce negative feelings about lung cancer, increasing willingness to get screened.

LungTalk does not cause physical side effects, as it is not a medication. This computer-based tool guides decisions, focusing on education rather than treatment, making it very safe to use. No reports of problems have emerged from using LungTalk. It simply helps individuals make informed choices about lung cancer screening. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about LungTalk because it offers a personalized approach to increasing lung cancer screening rates. Unlike the standard non-tailored educational videos, LungTalk is a tailored health communication tool that uses a 10-15 minute interactive session to engage participants based on their individual characteristics and needs. This targeted approach is designed to enhance decision-making and encourage participation in lung cancer screening, potentially leading to earlier detection and better outcomes. By grounding its strategy in a conceptual model on lung cancer screening participation, LungTalk aims to make a significant impact on public health by improving screening rates.

What evidence suggests that this trial's treatments could be effective for increasing lung cancer screening?

Studies have shown that LungTalk, a computer-based tool, helps people make decisions about lung cancer screening. In this trial, participants in one arm will receive the LungTalk intervention, which uses personalized information to explain the importance of screening, potentially encouraging more participation. The tool carefully uses language and images to reduce intimidation and enhance effectiveness. Initial findings suggest that personalized approaches can significantly increase screening rates among high-risk groups. The goal is to help more people get screened for lung cancer by making the information clear and relevant. ^{2 5 6 7 8}

Who Is on the Research Team?

Lisa Carter-Bawa, PhD

Principal Investigator

Hackensack Meridian Health

Are You a Good Fit for This Trial?

The INSPIRE-Lung Study is for individuals who have a history of heavy smoking (at least 20 pack-years), including current smokers or those who quit within the last 15 years. It's not for people who've already had lung cancer screening, are being monitored for lung nodules, have been diagnosed with lung cancer, or have impaired decision-making.

Inclusion Criteria

You have smoked an average of one pack a day for 20 years or more.

I am a current smoker or quit smoking within the last 15 years.

Exclusion Criteria

I am capable of making my own decisions.

I have had a low-dose CT scan for lung cancer and am being monitored for lung nodules.

I have been diagnosed with lung cancer.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive either the tailored health communication intervention 'LungTalk' or the non-tailored ACS Lung Screening Informational Video

6 months

Online intervention

Follow-up

Participants are monitored for effectiveness of the intervention, including self-efficacy, perceived risk, and screening uptake

6 months

Long-term Monitoring

Reaching screening eligible individuals via social media and measuring engagement metrics

Up to 4 years

What Are the Treatments Tested in This Trial?

Interventions

• LungTalk
• Non-tailored intervention - Standard of practice

Trial Overview This study tests 'LungTalk', a communication intervention aimed at increasing lung cancer screening rates among high-risk groups using Facebook-targeted advertisements. It compares LungTalk to standard practices without tailored interventions.

How Is the Trial Designed?

Group I: Tailored health communication intervention (LungTalk) Experimental Treatment 1 Intervention

Participants will receive the tailored health intervention "LungTalk". LungTalk is a 10-15 minute long computer-tailored health communication and decision-making tool that is theoretically grounded in the Conceptual Model on Lung Cancer Screening Participation.

Group II: Non-tailored Intervention Active Control 1 Intervention

Participants will receive non-tailored American Cancer Society (ACS) Lung Screening Informational Video as per standard of care. ACS Lung Screening Informational Video (ACS LSIV) is a non-tailored 5-minute video from the American Cancer Society about lung cancer screening designed for the lay individual.

LungTalk is already approved in United States for the following indications:

Approved in United States as LungTalk for:

• Lung Cancer Screening Awareness
• Education and Support

Who Is Running the Clinical Trial?

Hackensack Meridian Health

Lead Sponsor

Trials

141

Recruited

42,900+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Published Research Related to This Trial

A randomized controlled trial is being conducted to evaluate the effectiveness of a social media-based intervention called LungTalk, aimed at increasing awareness and knowledge about lung cancer screening among high-risk individuals.

The study addresses the low uptake of lung cancer screening despite evidence from the National Lung Screening Trial showing that low-dose computed tomography can reduce lung cancer mortality, highlighting the potential of social media to reach underserved populations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Leveraging social media to increase lung cancer screening awareness, knowledge and uptake among high-risk populations (The INSPIRE-Lung Study): Study protocol of design and methods of a community-based randomized controlled trial. Lisa, CB., Banerjee, SC., Ostroff, JS., et al.[2023]

A group education class on lung cancer screening significantly improved participants' knowledge, with an average increase of 0.9 correct responses on a true-false quiz after the class, based on surveys from 680 participants.

Approximately 70% of participants felt they had enough information to make informed decisions about lung cancer screening after attending the class, indicating that this educational approach effectively enhances decision-making capacity.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effectiveness of a Patient Education Class to Enhance Knowledge about Lung Cancer Screening: a Quality Improvement Evaluation. Sakoda, LC., Meyer, MA., Chawla, N., et al.[2021]

The Risk-Based NLST Outcomes Tool (RNOT) helps individuals understand their personalized risk of lung cancer diagnosis and death, which can aid in making informed decisions about screening.

Participants in the study found the RNOT useful for screening decisions, although they expressed confusion about risk changes and indicated that there was no level of false-positive risk that would deter them from screening.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Patient Perspectives on the Risk-Based NLST Outcomes Tool for Lung Cancer Screening. Roberts, MC., Seaman, EL., Klein, WMP., et al.[2022]

The Lung AIR intervention effectively increased knowledge and reduced fear about lung cancer screening among 292 participants, demonstrating its feasibility as a community-based educational program.

One-on-one phone sessions were particularly effective, leading to greater increases in participants' intention to complete screening compared to in-person group sessions, especially among those with lower income and higher smoking rates.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Adapting Community Educational Programs During the COVID-19 Pandemic: Comparing the Feasibility and Efficacy of a Lung Cancer Screening Educational Intervention by Mode of Delivery. Bouchard, EG., Saad-Harfouche, FG., Clark, N., et al.[2023]

A single-page, paper-based encounter decision aid (EDA) used during shared decision-making visits for lung cancer screening significantly reduced patient decisional conflict, as indicated by a drop in the Decisional Conflict Scale score from 35.0 to 0.2 (p < 0.001).

While 28% of patients understood the mortality benefit of lung cancer screening after the visit, a much higher percentage (82%) grasped the frequency of abnormal screening results, highlighting the need for improved patient education on the mortality benefits of screening.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pilot Study of an Encounter Decision Aid for Lung Cancer Screening. Ito Fukunaga, M., Balwan, A., Janis, JA., et al.[2023]

A focus group study involving 54 participants from Appalachian Kentucky revealed that most individuals were previously unaware of lung cancer screening with low-dose computed tomography (LDCT), highlighting the need for effective awareness campaigns.

Participants emphasized the importance of messaging that includes personal testimonies, hope, and the benefits of early detection, suggesting that communication from trusted healthcare providers is crucial for promoting lung cancer screening.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Identifying Community Perspectives for a Lung Cancer Screening Awareness Campaign in Appalachia Kentucky: The Terminate Lung Cancer (TLC) Study. Cardarelli, R., Roper, KL., Cardarelli, K., et al.[2018]

The study aims to implement a tailored approach to shared decision-making (SDM) for lung cancer screening (LCS) within the VA New England Health Care Network, addressing barriers at multiple levels to enhance patient-centered care.

By evaluating the effectiveness of this multilevel implementation strategy, the research seeks to improve the quality of SDM for LCS, potentially informing nationwide practices and promoting better patient-provider interactions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Implementing Shared Decision-Making for Lung Cancer Screening across a Veterans Health Administration Hospital Network: A Hybrid Effectiveness-Implementation Study Protocol. Khanna, A., Fix, GM., McCullough, MB., et al.[2022]

A randomized trial involving 298 Maryland Tobacco Quitline callers showed that providing lung cancer screening (LCS) education through print materials led to higher engagement (75% read the materials) compared to web-based materials (61.6%).

Despite similar rates of scheduling or completing LCS between the two groups (around 43%), the study highlights that offering educational materials in preferred formats (print or web) can enhance awareness and potentially increase screening rates among eligible individuals.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The tobacco quitline setting as a teachable moment: The Educating Quitline Users About Lung (EQUAL) cancer screening randomized trial. Webster, M., Whealan, J., Williams, RM., et al.[2023]

A systematic review of 24 studies involving 6689 patients found that only 57% adhered to Lung-RADS-recommended screening intervals, indicating suboptimal compliance that could reduce the effectiveness of lung cancer screening.

Adherence rates were significantly higher for patients with Lung-RADS scores of 3 to 4 compared to those with scores of 1 to 2, suggesting that patients with more concerning findings are more likely to follow up with screenings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Patient Adherence to Lung CT Screening Reporting & Data System-Recommended Screening Intervals in the United States: A Systematic Review and Meta-Analysis. Lin, Y., Fu, M., Ding, R., et al.[2022]

Citations

1. sciencedirect.com sciencedirect.com/science/article/pii/S2666364323001285

A Brief Report Case Study Using the Lung Cancer Stigma ... The LCS-CAT considers language, imagery, and context and was used to audit a public-facing health communication and decision support tool called LungTalk.

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC7671845/

Computer-Tailored Decision Support Tool for Lung Cancer ... LungTalk is a computer-tailored decision support tool that is theoretically grounded in the Conceptual Model on Lung Cancer Screening ...

3. cancernetwork.com cancernetwork.com/view/combatting-stigmatization-to-increase-lung-cancer-screening-access

Combatting Stigmatization to Increase Lung Cancer ... According to findings published in JTO Clinical Research and Reports, applying the Lung Cancer Stigma Communications Assessment Tool to LungTalk ...

4. nlcrt.org nlcrt.org/resource/effective-communication-about-lung-cancer-screening-without-iatrogenic-stigma-a-brief-report-case-study-using-the-lung-cancer-stigma-communications-assessment-tool-of-lungtalk/

A Brief Report Case Study Using the Lung Cancer Stigma ... Effective Communication About Lung Cancer Screening Without Iatrogenic ... Lung Cancer Stigma Communications Assessment Tool of LungTalk. Effective ...

5. mdpi.com mdpi.com/1660-4601/22/8/1250

Effectiveness of Technology-Based Interventions in ... Potential of Technology in Promoting Lung Cancer Screening. 4.1.1. Important Features for Consideration in Tool and Intervention Design. Most tools described in ...

6. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/38029025/

A Brief Report Case Study Using the Lung Cancer Stigma ... ... Lung Cancer Stigma Communications Assessment Tool of LungTalk. JTO ... Keywords: Communication; Lung cancer; Lung cancer screening; Stigma.

7. withpower.com withpower.com/trial/phase-lung-neoplasms-5-2023-36bde

LungTalk for Increasing Lung Cancer Screening These findings imply that similar tools, such as LungTalk, may also be effective in increasing lung cancer screening by facilitating better communication and ...

8. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12386249/

Effectiveness of Technology-Based Interventions in Promoting ... Carter-Harris et al. developed LungTalk, a web-based tool that aimed to increase awareness and prepare individuals to make lung cancer screening ...